دورية أكاديمية
Treatment of acromegaly with oral octreotide.
| العنوان: | Treatment of acromegaly with oral octreotide. |
|---|---|
| المؤلفون: | Remba-Shapiro I; Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: iremba@mgh.harvard.edu., Nachtigall LB; Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: lnachtigall@partners.org. |
| المصدر: | Best practice & research. Clinical endocrinology & metabolism [Best Pract Res Clin Endocrinol Metab] 2024 Jul; Vol. 38 (4), pp. 101888. Date of Electronic Publication: 2024 Feb 22. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101120682 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1594 (Electronic) Linking ISSN: 1521690X NLM ISO Abbreviation: Best Pract Res Clin Endocrinol Metab Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : Amsterdam : Elsevier Original Publication: Amsterdam : Harcourt Publishers, c2001- |
| مواضيع طبية MeSH: | Octreotide*/administration & dosage , Octreotide*/therapeutic use , Octreotide*/adverse effects , Acromegaly*/drug therapy , Antineoplastic Agents, Hormonal*/adverse effects , Antineoplastic Agents, Hormonal*/administration & dosage , Antineoplastic Agents, Hormonal*/therapeutic use, Humans ; Administration, Oral ; Human Growth Hormone/administration & dosage ; Adenoma/drug therapy ; Adenoma/complications ; Growth Hormone-Secreting Pituitary Adenoma/drug therapy ; Growth Hormone-Secreting Pituitary Adenoma/complications |
| مستخلص: | Acromegaly is a rare disease caused by a growth hormone excess, usually due to a secreting pituitary adenoma. Somatostatin receptor ligands (SRL) are the mainstay of medical therapy for patients with acromegaly who fail to achieve biochemical control post-operatively or are not eligible for surgical treatment. SRLs are typically administered as monthly injections and have shown to be effective in maintaining biochemical and radiological control of acromegaly. However, these injections may cause local adverse events and are associated with increased psychological burden in some patients. Oral octreotide provides a new alternative for patients responding to injectable SRLs. This new formulation has shown to have similar safety and efficacy profiles compared to injectable SRLs and may be a preferable option for some patients with acromegaly. The aim of this review is to provide an overview of the role of oral octreotide in the management of acromegaly. Competing Interests: Declaration of Competing Interest Lisa B. Nachtigall has received grant support from Recordati and Amryt and has served as a consultant for Crinetics. (Copyright © 2024. Published by Elsevier Ltd.) |
| فهرسة مساهمة: | Keywords: IGF-1; acromegaly; growth hormone; oral octreotide; somatostatin receptor ligands |
| المشرفين على المادة: | RWM8CCW8GP (Octreotide) 0 (Antineoplastic Agents, Hormonal) 12629-01-5 (Human Growth Hormone) |
| تواريخ الأحداث: | Date Created: 20240305 Date Completed: 20240720 Latest Revision: 20240720 |
| رمز التحديث: | 20240722 |
| DOI: | 10.1016/j.beem.2024.101888 |
| PMID: | 38443224 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1878-1594 |
|---|---|
| DOI: | 10.1016/j.beem.2024.101888 |